Access to medicines in Burkina Faso under the agreement on trade-related aspects of intellectual property rights and the Economic Partnership Agreement

Show simple item record

dc.contributor.advisor Kabre, Rimdolmsom Jonathan
dc.contributor.coadvisor Oluyeju, Femi
dc.contributor.postgraduate Ouédraogo, Bertille Charlotte
dc.date.accessioned 2023-11-28T12:12:48Z
dc.date.available 2023-11-28T12:12:48Z
dc.date.created 2023-12-08
dc.date.issued 2023
dc.description Mini Dissertation (LLM (International Trade and Investment Law))--University of Pretoria, 2023. en_US
dc.description.abstract Cooperation between the European Union and Burkina Faso began several decades ago. Trade relations between the two partners are significant, with the European Union representing Burkina Faso's third-largest economic partner. Negotiated under the aegis of ECOWAS, the Economic Partnership Agreement signed in 2014 between the West African states and the European Union will govern relations between the European Union and Burkina Faso once it comes into force. With this in mind, this study sets out to analyze the impact of this agreement in a key area: access to medicines. The study takes into account both the TRIPS agreement and the EPA because according to the Cotonou Agreement, which precedes and justifies the EPA, the TRIPS agreement is the reference in terms of intellectual property rights. As a least-developed country and signatory to the TRIPS agreement, Burkina Faso has access to numerous flexibilities that may enable it to adopt health policies favorable to its situation. With regard to access to medicines, the TRIPS agreement states that patents protect inventors. There is a clear link between intellectual property and access to medicines. There are two opposing viewpoints on this subject. One is that there is a direct link between a weakened patent system and access to medicines, while the other is that patentability needs to be strengthened to encourage drug research. After an in-depth presentation of the main flexibilities of the TRIPS Agreement, this study will determine which one is suitable for Burkina Faso and which may be difficult to apply given the country's lack of resources. After studying the case of other least-developed countries in Africa, an appropriate course of action will be proposed to the EPA to facilitate access to medicines in Burkina Faso. Finally, the conclusion of this research will be to make proposals along the same lines that Burkina Faso could apply at the national level, but also with the help of its collaborators such as the EU, under the aegis of the EPA. en_US
dc.description.availability Unrestricted en_US
dc.description.degree LLM (International Trade and Investment Law) en_US
dc.description.department Centre for Human Rights en_US
dc.description.faculty Faculty of Laws en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.identifier.citation * en_US
dc.identifier.other D2023 en_US
dc.identifier.uri http://hdl.handle.net/2263/93497
dc.language.iso en en_US
dc.publisher University of Pretoria
dc.rights © 2023 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
dc.subject UCTD en_US
dc.subject European Union en_US
dc.subject Burkina Faso en_US
dc.subject Access to medicines en_US
dc.subject Trade agreement en_US
dc.subject Intellectual property rights en_US
dc.title Access to medicines in Burkina Faso under the agreement on trade-related aspects of intellectual property rights and the Economic Partnership Agreement en_US
dc.type Dissertation en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record